EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion

Xiaomeng Xu, Mengting Wu, Fang Zhao, Jipeng Li, Ye Chen, Rui Lu, Yang Zha, Yuting Zhang, Hongbin Peng, Haichao Cao, Lijie He

Nephrology Dialysis Transplantation · 2026-10-30 · 41 (11) · 1988-1998

DOI: 10.1093/ndt/gfag065 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background and hypothesis Primary membranous nephropathy (MN) and diabetes mellitus (DM) are common comorbidities, yet the impact of DM on the response to anti-CD20 monoclonal antibody therapy in MN remains unclear. We hypothesized that despite comparable B-cell depletion, MN patients with comorbid DM would exhibit a reduced treatment response compared to nondiabetic MN patients. Methods In this retrospective cohort study, we included adults with primary MN who received at least one complete course of anti-CD20 antibody therapy. Propensity score matching (1:2) was applied based on age, sex, baseline estimated glomerular filtration rate, urinary protein, and PLA2R antibody status. The primary outcome was remission (complete or partial) of proteinuria at 3, 6, 9, and 12 months. Secondary outcomes included immunological remission, B-cell depletion, and changes in renal parameters. Multivariable logistic regression, Kaplan–Meier analysis, and subgroup analyses were used to compare outcomes between MN patients with (MN + DM) and without diabetes (MN). Results After matching, 207 patients were included (72 MN + DM, 135 MN). B-cell depletion and immunological remission rates showed no statistically significant differences between groups over the 12-month follow-up period. However, MN patients had significantly higher overall remission rates at 9 months [94% vs. 77%; odds ratio (OR) = 4.55, 95% confidence interval (CI) = 1.52–12.50, P < 0.01] and at 12 months (97% vs. 86%; OR: 5.26, 95% CI: 1.25–20.00, P < 0.05). Subgroup analyses confirmed consistently poorer responses in diabetic patients across multiple strata. Safety profiles were similar between groups. Conclusion Despite equivalent B-cell depletion, MN with DM patients show a reduced response to anti-CD20 antibody therapy relative to nondiabetic patients, underscoring that tight glycemic control, early supplementary anti-CD20 dosing for poor response, and combined immunosuppressive regimens may enhance their clinical outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →